# Oyster Point Pharma Inc. (OYST)

Source: https://www.quantisnow.com/company/OYST
Generated: 2026-11-08T03:51:02.300Z

- Ticker: OYST
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2019
- Website: oysterpointrx.com

## About

Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that has completed Phase III clinical trial for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratopathy. Oyster Point Pharma, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.

## Latest OYST news and filings

- 2024-02-21 17:02 UTC [Market Insight] [Health Care Becomes Most Overweighted Sector As Hedge Funds Crowd Into Magnificent 7](https://www.quantisnow.com/insight/health-care-becomes-most-overweighted-sector-as-hedge-funds-crowd-5279095)
- 2023-02-14 21:59 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Oyster Point Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-oyster-point-pharma-inc-4065165)
- 2023-02-14 15:05 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Oyster Point Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-oyster-point-pharma-inc-4057170)
- 2023-01-13 22:10 UTC [SEC Form 15-12G filed by Oyster Point Pharma Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-oyster-point-pharma-inc-3912193)
- 2023-01-13 22:06 UTC [SEC Form 8-K] [Oyster Point Pharma Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits (Amendment)](https://www.quantisnow.com/insight/oyster-point-pharma-inc-filed-sec-form-8-k-termination-of-3912145)
- 2023-01-13 21:09 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Oyster Point Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-oyster-point-pharma-inc-3911547)
- 2023-01-09 21:32 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Oyster Point Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-oyster-point-pharma-inc-3891070)
- 2023-01-06 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Oyster Point Pharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-oyster-point-pharma-inc-3881606)
- 2023-01-05 21:32 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Oyster Point Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-oyster-point-pharma-inc-3879744)
- 2023-01-05 21:30 UTC [SEC Form 4] [SEC Form 4 filed by Invopps Gp Iv, L.L.C.](https://www.quantisnow.com/insight/sec-form-4-filed-by-invopps-gp-iv-llc-3879682)
- 2023-01-04 23:11 UTC [SEC Form 4] [SEC Form 4 filed by Versant Venture Capital Vi, L.P.](https://www.quantisnow.com/insight/sec-form-4-filed-by-versant-venture-capital-vi-lp-3873774)
- 2023-01-04 22:16 UTC [SEC Form 4] [SEC Form 4: Behbahani Ali returned 13,639 shares to the company, closing all direct ownership in the company (for tax liability)](https://www.quantisnow.com/insight/sec-form-4-behbahani-ali-returned-13639-shares-to-the-3873041)
- 2023-01-04 22:14 UTC [SEC Form 4] [SEC Form 4 filed by New Enterprise Associates 14, L.P.](https://www.quantisnow.com/insight/sec-form-4-filed-by-new-enterprise-associates-14-lp-3873003)
- 2023-01-04 22:10 UTC [SEC Form 4] [SEC Form 4: Weisner Aimee S returned 36,764 shares to the company, closing all direct ownership in the company (for tax liability)](https://www.quantisnow.com/insight/sec-form-4-weisner-aimee-s-returned-36764-shares-to-3872900)
- 2023-01-04 22:08 UTC [SEC Form 4] [SEC Form 4: Tsai Benjamin returned 3,573 shares to the company, closing all direct ownership in the company (withholding obligation)](https://www.quantisnow.com/insight/sec-form-4-tsai-benjamin-returned-3573-shares-to-the-3872883)
- 2023-01-04 22:08 UTC [SEC Form 4] [SEC Form 4: Santel Donald J returned 8,198 shares to the company, closing all direct ownership in the company to cover withholding tax](https://www.quantisnow.com/insight/sec-form-4-santel-donald-j-returned-8198-shares-to-3872854)
- 2023-01-04 22:07 UTC [SEC Form 4] [SEC Form 4: Ozawa Clare returned 14,637 shares to the company, closing all direct ownership in the company (withholding tax)](https://www.quantisnow.com/insight/sec-form-4-ozawa-clare-returned-14637-shares-to-the-3872840)
- 2023-01-04 22:06 UTC [SEC Form 4] [SEC Form 4: Nau Jeffrey covered exercise/tax liability with 2,607 shares and returned 48,975 shares to the company, closing all direct ownership in the company to satisfy withholding tax](https://www.quantisnow.com/insight/sec-form-4-nau-jeffrey-covered-exercisetax-liability-with-2607-3872817)
- 2023-01-04 22:05 UTC [SEC Form 4] [SEC Form 4: Murray Mark Anthony returned 122,086 shares to the company, closing all direct ownership in the company to satisfy withholding tax](https://www.quantisnow.com/insight/sec-form-4-murray-mark-anthony-returned-122086-shares-to-3872806)
- 2023-01-04 22:04 UTC [SEC Form 4] [SEC Form 4: Lochner Daniel covered exercise/tax liability with 938 shares and returned 20,236 shares to the company, closing all direct ownership in the company (tax liability)](https://www.quantisnow.com/insight/sec-form-4-lochner-daniel-covered-exercisetax-liability-with-938-3872786)
- 2023-01-04 22:03 UTC [SEC Form 4] [SEC Form 4: Eliades George Christopher returned 28,624 shares to the company, closing all direct ownership in the company (tax liability)](https://www.quantisnow.com/insight/sec-form-4-eliades-george-christopher-returned-28624-shares-to-3872757)
- 2023-01-04 22:02 UTC [SEC Form 4] [SEC Form 4: Atieh Michael G returned 8,671 shares to the company, closing all direct ownership in the company (withholding obligation)](https://www.quantisnow.com/insight/sec-form-4-atieh-michael-g-returned-8671-shares-to-3872740)
- 2023-01-03 14:52 UTC [SEC Form 25-NSE filed by Oyster Point Pharma Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-oyster-point-pharma-inc-3862693)
- 2023-01-03 14:26 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Oyster Point Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-oyster-point-pharma-inc-3862509)
- 2023-01-03 14:26 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Oyster Point Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-oyster-point-pharma-inc-3862504)
- 2023-01-03 14:24 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Oyster Point Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-oyster-point-pharma-inc-3862486)
- 2023-01-03 14:22 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Oyster Point Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-oyster-point-pharma-inc-3862480)
- 2023-01-03 14:18 UTC [SEC Form POS AM filed by Oyster Point Pharma Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-oyster-point-pharma-inc-3862460)
- 2023-01-03 14:12 UTC [SEC Form 8-K] [Oyster Point Pharma Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/oyster-point-pharma-inc-filed-sec-form-8-k-termination-of-3862414)
- 2023-01-03 14:09 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by Oyster Point Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-oyster-point-pharma-inc-3862397)
- 2022-12-23 11:30 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by Oyster Point Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-oyster-point-pharma-inc-3840230)
- 2022-12-22 22:14 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9 filed by Oyster Point Pharma Inc.](https://www.quantisnow.com/insight/sec-form-sc-14d9-filed-by-oyster-point-pharma-inc-3839489)
- 2022-12-09 12:00 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by Oyster Point Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-oyster-point-pharma-inc-3787406)
- 2022-12-07 00:05 UTC [SEC Form 4] [SEC Form 4: Nau Jeffrey covered exercise/tax liability with 8,938 shares, decreasing direct ownership by 6% to 148,660 units to cover withholding tax (Amendment)](https://www.quantisnow.com/insight/sec-form-4-nau-jeffrey-covered-exercisetax-liability-with-8938-3775470)
- 2022-12-06 13:50 UTC [SEC Form 4] [SEC Form 4: Lochner Daniel covered exercise/tax liability with 3,258 shares, decreasing direct ownership by 4% to 74,463 units (for tax liability)](https://www.quantisnow.com/insight/sec-form-4-lochner-daniel-covered-exercisetax-liability-with-3258-3771618)
- 2022-12-05 22:36 UTC [SEC Form 4] [SEC Form 4: Nau Jeffrey covered exercise/tax liability with 6,217 shares, decreasing direct ownership by 4% to 151,381 units to satisfy withholding obligation](https://www.quantisnow.com/insight/sec-form-4-nau-jeffrey-covered-exercisetax-liability-with-6217-3769266)
- 2022-12-02 13:00 UTC [Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/oyster-point-pharma-inc-reports-inducement-grants-under-nasdaq-listing-3759886)
- 2022-12-01 12:38 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9 filed by Oyster Point Pharma Inc.](https://www.quantisnow.com/insight/sec-form-sc-14d9-filed-by-oyster-point-pharma-inc-3754100)
- 2022-11-21 18:29 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Oyster Point Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-oyster-point-pharma-inc-3714897)
- 2022-11-16 21:24 UTC [SEC Form SC14D9C filed by Oyster Point Pharma Inc.](https://www.quantisnow.com/insight/sec-form-sc14d9c-filed-by-oyster-point-pharma-inc-3698250)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/OYST
- Earnings history: https://www.quantisnow.com/earnings/OYST
- Dividend history: https://www.quantisnow.com/dividends/OYST
- Insider transactions: https://www.quantisnow.com/insiders/OYST
- Options chain: https://www.quantisnow.com/options/OYST
- SEC 8-K filings only: https://www.quantisnow.com/company/OYST/8-k
- RSS and alerts for OYST: https://www.quantisnow.com/docs/rss-feeds.md